Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M.

Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.

PMID:
25862517
2.

Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.

Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists' Group of the Netherlands (BOOG).

Eur J Cancer. 2013 Oct;49(15):3102-10. doi: 10.1016/j.ejca.2013.06.012. Epub 2013 Jul 10.

PMID:
23850450
3.

Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer.

Buijsen J, Lammering G, Jansen RL, Beets GL, Wals J, Sosef M, Den Boer MO, Leijtens J, Riedl RG, Theys J, Lambin P.

Radiother Oncol. 2013 May;107(2):184-8. doi: 10.1016/j.radonc.2013.03.023. Epub 2013 May 3.

PMID:
23647753
4.

Reliability of receptor assessment on core needle biopsy in breast cancer patients.

Seferina SC, Nap M, van den Berkmortel F, Wals J, Voogd AC, Tjan-Heijnen VC.

Tumour Biol. 2013 Apr;34(2):987-94. doi: 10.1007/s13277-012-0635-5. Epub 2012 Dec 27.

PMID:
23269610
5.

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P.

J Clin Oncol. 2011 Aug 20;29(24):3247-54. doi: 10.1200/JCO.2010.32.7254. Epub 2011 Jul 18.

PMID:
21768453
6.

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.

Lalisang RI, Erdkamp FL, Rodenburg CJ, Knibbeler-van Rossum CT, Nortier JW, van Bochove A, Slee PH, Voest EE, Wils JA, Wals J, Loosveld OJ, Smals AE, Blijham GH, Tjan-Heijnen VC, Schouten HC.

Breast Cancer Res Treat. 2011 Jul;128(2):437-45. doi: 10.1007/s10549-011-1558-3. Epub 2011 May 17.

PMID:
21584666
7.

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ; Cooperating investigators of the Dutch TEAM trial.

Ann Oncol. 2010 May;21(5):974-82. doi: 10.1093/annonc/mdp419. Epub 2009 Oct 29.

PMID:
19875752
8.

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ; Dutch Colorectal Cancer Group study.

Br J Cancer. 2008 Jul 22;99(2):275-82. doi: 10.1038/sj.bjc.6604461. Epub 2008 Jul 1.

9.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD).

Lancet. 2008 Mar 22;371(9617):1007-16. doi: 10.1016/S0140-6736(08)60455-9.

10.

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ.

Lancet. 2007 Jul 14;370(9582):135-42.

PMID:
17630036
11.

Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Akkermans-Vogelaar JM, Punt CJ.

Ann Oncol. 2006 Oct;17(10):1523-8. Epub 2006 Jul 27.

PMID:
16873425
12.

Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL.

Scharnhorst V, Wals J, Beverloo HB, Langerak AW, van der Velden VH.

Leuk Res. 2006 Feb;30(2):245-6. Epub 2005 Aug 2. No abstract available.

PMID:
16081157
13.

Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.

Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouché O, Morin T, Baila L, van Cutsem E, Bedenne L.

Lancet Oncol. 2005 Jul;6(7):459-68.

PMID:
15992694
14.

The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.

Peters FP, Fickers MM, Erdkamp FL, Wals J, Wils JA, Schouten HC.

Ann Hematol. 2001 Jul;80(7):406-10.

PMID:
11529466
15.

Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.

Peters FP, Lalisang RI, Fickers MM, Erdkamp FL, Wils JA, Houben SG, Wals J, Schouten HC.

Ann Hematol. 2001 Mar;80(3):155-9.

PMID:
11320900
16.

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.

Lalisang RI, Voest EE, Wils JA, Nortier JW, Erdkamp FL, Hillen HF, Wals J, Schouten HC, Blijham GH.

Br J Cancer. 2000 Jun;82(12):1914-9.

17.

Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.

Wils J, van Geuns H, Stoot J, Bergmans M, Boschma F, Bron H, Degen J, Erdkamp F, van Erp J, Haest J, Iding R, Lalisang F, de Pree N, de Rooy C, Snijders M, Schepers J, Vreeswijk J, Wals J, Werter M, Wetzels L, Smeets J, Schouten L.

Anticancer Drugs. 1999 Mar;10(3):257-61.

PMID:
10327029
19.

Rydberg-electron wave-packet dynamics in parallel electric and magnetic fields and evidence for stabilization.

Fielding HH, Wals J, van der Zande WJ, van Linden van den Heuvell HB.

Phys Rev A. 1995 Jan;51(1):611-619. No abstract available.

PMID:
9911621
20.

Observation of Rydberg wave packet dynamics in a Coulombic and magnetic field.

Wals J, Fielding HH, Christian JF, Snoek LC, van der Zande WJ, van Linden van den Heuvell HB.

Phys Rev Lett. 1994 Jun 13;72(24):3783-3786. No abstract available.

PMID:
10056296

Supplemental Content

Loading ...
Support Center